6th Digital Pharma & Life Sciences Conference 2011

22 February 2011, Wiesbaden, Germany.
For the sixth time Microsoft and its partners will be holding the Digital Pharma & Life Sciences conference. The lecture event and exhibition is aimed at the pharmaceutical, chemical and life sciences industries, showing current projects and innovative technologies that support greater sustainability, cost efficiency and competitiveness in and through IT.

IT has become a critical competitive factor as an instrument for sustainable climate and environmental protection. The framework is set by international initiatives by industries and governments: for example more than 500 investors request global listed companies to report their CO2 relevant business data through the Carbon Disclosure Project (CDP) from the UK. Global initiatives for Green Chemistry such as the conventions from Stockholm, Rotterdam and Basel, the OECD and the regulatory authorities of developed countries are working to create global standards for sustainable risk and chemicals management.

For this reason, the Digital Pharma & Life Sciences conference 2011 is focussing on the topics "Green IT – Green Chemistry". With the focus on "Green in IT", experts will discuss latest developments of Green IT technologies on the basis of recent successful projects in order to make processes more efficient, save resources and energy and thereby reduce costs. These include concepts for IT virtualization in controlling chemical production or cloud computing for pharmaceutical research.

The "Green through IT" presentations will show pioneering Green Chemistry projects that ensure sustainability in production, research and development and overall global supply chains. Leading companies from the chemical, pharmaceutical and life sciences industries demonstrate how they coordinate production and logistics processes better through intelligent technologies, plan forward-looking and therefore design initiatives for more economically measurable sustainability.

The conference takes place on 22nd February 2011 in the Kurhaus Wiesbaden and is aimed at decision makers and experts from the fields of IT and business management, research and development, business development management, product management, production, quality management, sales and controlling.

During the accompanying exhibition, the partners of the Digital Pharma & Life Sciences initiative will show latest IT technologies and reference projects. On the eve of the conference on 21st February 2011, an exclusive dinner will take place with all the speakers, conference participants and partners of the initiative.

Further information for registration, the agenda and logistic details are available at:
http://www.digitalpharma.de

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Sanofi completes acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The acquisition of Synthorx perfectly aligns w...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...

AstraZeneca divests rights to established hyperten…

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Ze...

Botanical drug is shown to help patients with head…

In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are locat...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...